Myeloid-derived Suppressor Cells in the Tumor Microenvironment: Expect the Unexpected

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2015 Jul 14

PMID 26168215

Citations 582

Authors

Douglas Marvel

Dmitry I Gabrilovich

Affiliations

Soon will be listed here.

Abstract

Our understanding of the role of myeloid-derived suppressor cells (MDSCs) in cancer is becoming increasingly complex. In addition to their eponymous role in suppressing immune responses, they directly support tumor growth, differentiation, and metastasis in a number of ways that are only now beginning to be appreciated. It is because of this increasingly complex role that these cells may become an important factor in the treatment of human cancer. In this Review, we discuss the most pertinent and controversial issues of MDSC biology and their role in promoting cancer progression and highlight how these cells may be used in the clinic, both as prognostic factors and as therapeutic targets.

Citing Articles

Clinical significance of the tumor microenvironment on immune tolerance in gastric cancer.

He X, Guan X, Li Y Front Immunol. 2025; 16:1532605.

PMID: 40028336 PMC: 11868122. DOI: 10.3389/fimmu.2025.1532605.

Mechanisms of Resistance to Anti-PD-1 Immunotherapy in Melanoma and Strategies to Overcome It.

Zielinska M, Ciazynska M, Sulejczak D, Rutkowski P, Czarnecka A Biomolecules. 2025; 15(2).

PMID: 40001572 PMC: 11853485. DOI: 10.3390/biom15020269.

GLP1 alleviates oleic acid-propelled lipocalin-2 generation by tumor-infiltrating CD8 T cells to reduce polymorphonuclear MDSC recruitment and enhances viral immunotherapy in pancreatic cancer.

Wu J, Qian P, Han Y, Xu C, Xia M, Zhan P Cell Mol Immunol. 2025; 22(3):282-299.

PMID: 39910336 PMC: 11868399. DOI: 10.1038/s41423-025-01260-3.

Plasma membrane-coated nanoparticles and membrane vesicles to orchestrate multimodal antitumor immunity.

Ito Y, Kasuya H, Kataoka M, Nakamura N, Yoshikawa T, Nakashima T J Immunother Cancer. 2025; 13(1).

PMID: 39864848 PMC: 11784344. DOI: 10.1136/jitc-2024-010005.

The Estrogen-Immune Interface in Endometriosis.

Greygoose E, Metharom P, Kula H, Seckin T, Seckin T, Ayhan A Cells. 2025; 14(1.

PMID: 39791759 PMC: 11720315. DOI: 10.3390/cells14010058.

References

Elkabets M, Ribeiro V, Dinarello C, Ostrand-Rosenberg S, Di Santo J, Apte R . IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function. Eur J Immunol. 2010; 40(12):3347-57. PMC: 3373225. DOI: 10.1002/eji.201041037. View

Tarhini A, Edington H, Butterfield L, Lin Y, Shuai Y, Tawbi H . Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One. 2014; 9(2):e87705. PMC: 3912016. DOI: 10.1371/journal.pone.0087705. View

Diaz-Montero C, Salem M, Nishimura M, Garrett-Mayer E, Cole D, Montero A . Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2008; 58(1):49-59. PMC: 3401888. DOI: 10.1007/s00262-008-0523-4. View

Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L . Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med. 2007; 13(7):828-35. PMC: 2135607. DOI: 10.1038/nm1609. View

Mishalian I, Bayuh R, Levy L, Zolotarov L, Michaeli J, Fridlender Z . Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression. Cancer Immunol Immunother. 2013; 62(11):1745-56. PMC: 11028422. DOI: 10.1007/s00262-013-1476-9. View

Mahadevan N, Anufreichik V, Rodvold J, Chiu K, Sepulveda H, Zanetti M . Cell-extrinsic effects of tumor ER stress imprint myeloid dendritic cells and impair CD8⁺ T cell priming. PLoS One. 2012; 7(12):e51845. PMC: 3525659. DOI: 10.1371/journal.pone.0051845. View

Kusmartsev S, Su Z, Heiser A, Dannull J, Eruslanov E, Kubler H . Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2008; 14(24):8270-8. DOI: 10.1158/1078-0432.CCR-08-0165. View

Li H, Han Y, Guo Q, Zhang M, Cao X . Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol. 2008; 182(1):240-9. DOI: 10.4049/jimmunol.182.1.240. View

Gabrilovich D, Bronte V, Chen S, Colombo M, Ochoa A, Ostrand-Rosenberg S . The terminology issue for myeloid-derived suppressor cells. Cancer Res. 2007; 67(1):425. PMC: 1941787. DOI: 10.1158/0008-5472.CAN-06-3037. View

10.

Kimura T, McKolanis J, Dzubinski L, Islam K, Potter D, Salazar A . MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev Res (Phila). 2012; 6(1):18-26. PMC: 3536916. DOI: 10.1158/1940-6207.CAPR-12-0275. View

11.

Haverkamp J, Smith A, Weinlich R, Dillon C, Qualls J, Neale G . Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways. Immunity. 2014; 41(6):947-59. PMC: 4272664. DOI: 10.1016/j.immuni.2014.10.020. View

12.

Mirza N, Fishman M, Fricke I, Dunn M, Neuger A, Frost T . All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 2006; 66(18):9299-307. PMC: 1586106. DOI: 10.1158/0008-5472.CAN-06-1690. View

13.

Gujar S, Clements D, Dielschneider R, Helson E, Marcato P, Lee P . Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms. Br J Cancer. 2013; 110(1):83-93. PMC: 3887295. DOI: 10.1038/bjc.2013.695. View

14.

Liu C, Wang Y, Wang C, Feng P, Ko H, Liu Y . Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol. 2009; 136(1):35-45. DOI: 10.1007/s00432-009-0634-0. View

15.

Sinha P, Clements V, Ostrand-Rosenberg S . Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res. 2005; 65(24):11743-51. DOI: 10.1158/0008-5472.CAN-05-0045. View

16.

Hu C, Gan J, Zhang R, Cheng Y, Huang G . Up-regulated myeloid-derived suppressor cell contributes to hepatocellular carcinoma development by impairing dendritic cell function. Scand J Gastroenterol. 2010; 46(2):156-64. DOI: 10.3109/00365521.2010.516450. View

17.

Mauti L, Le Bitoux M, Baumer K, Stehle J, Golshayan D, Provero P . Myeloid-derived suppressor cells are implicated in regulating permissiveness for tumor metastasis during mouse gestation. J Clin Invest. 2011; 121(7):2794-807. PMC: 3223816. DOI: 10.1172/JCI41936. View

18.

Nefedova Y, Nagaraj S, Rosenbauer A, Muro-Cacho C, Sebti S, Gabrilovich D . Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res. 2005; 65(20):9525-35. PMC: 1351362. DOI: 10.1158/0008-5472.CAN-05-0529. View

19.

Rodriguez P, Hernandez C, Quiceno D, Dubinett S, Zabaleta J, Ochoa J . Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med. 2005; 202(7):931-9. PMC: 2213169. DOI: 10.1084/jem.20050715. View

20.

Zhao X, Rong L, Zhao X, Li X, Liu X, Deng J . TNF signaling drives myeloid-derived suppressor cell accumulation. J Clin Invest. 2012; 122(11):4094-104. PMC: 3484453. DOI: 10.1172/JCI64115. View